MNOV
MediciNova Inc.
NasdaqGM
People also watch:OPXACYTKTTHITRGTIDRA
6.200.13 (2.14%)

After hours: 6.20-0.00 (-0.02%) as of 4:46 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close6.07
Open6.03
Bid5.19 x 100
Ask0.00 x
52wk Range2.62 - 10.16
Day's Range5.97 - 6.36
Volume83,836
Avg Vol (3m)169,246
As of 4:00 PM EDT. Market closed.
  • MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16
    Zacks Small Cap Researchyesterday

    MNOV: Interim Analysis For Phase 2b Trial of MN-166 in Progressive MS in 4Q16

    MediciNova (MNOV) is developing MN-166 (ibudilast) for the treatment of primary and secondary progressive multiple sclerosis (PPMS and SPMS), amyotrophic lateral sclerosis (ALS), methamphetamine (MA) addiction, opioid dependence, and alcohol dependence. The drug is currently being tested in four separate clinical trials in the aforementioned indications with two trials recently completed in alcohol dependence and opioid dependence. MN-166 is an anti-inflammatory drug that has been used for over 20 years in Japan to treat asthma (Rolan et al., 2009) and post-stroke dizziness.

  • MediciNova, Inc. :MNOV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016
    Capital Cube2 months ago

    MediciNova, Inc. :MNOV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016

    Click here to see latest analysisMediciNova, Inc. reports financial results for the quarter ended March 31, 2016.AnalysisSummary numbers: Revenues of USD 0 million, Net Earnings of USD -3.38 million.The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.MNOV-US‘s earnings and EBITDA are both […] (Read more...) The post MediciNova, Inc. :MNOV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 appeared first on CapitalCube.